Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
brief summary
Valemetostat tosylate demonstrates antitumour activity in patients with peripheral T-cell lymphomas (PTCL) with a manageable safety profile. This Medical Access Program (MAP) offers an alternative treatment option for patients with PTCL who are ineligible for clinical trials by providing access to valmetostat tosylate, a medicinal product that has received marketing authorisation in Japan.
detailed description
A patient enrolled in the MAP can continue treatment until any of the following occurs, whichever comes first:
* Disease progression. * Unacceptable toxicity. * The benefit-risk no longer favors the individual. * Valemetostat tosylate becomes commercially available in the US or other treatment options become available. * Withdrawal of consent to continue treatment. * Pregnancy. * Physician discretion. * Death.
official title
Medical Access Program for Valemetostat Tosylate (DS 3201b) For The Treatment of Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) Originating From Mature T Cells (Including But Not Limited to Adult T-cell Leukemia/Lymphoma [ATLL], Anaplastic Large Cell Lymphoma [ALCL], Refractory Nodal T-Follicular Helper Lymphoma [nTFHL]), Regardless of CD30 Who Have Failed on 2 or More Lines of Treatments